[go: up one dir, main page]

SE0303513D0 - Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof - Google Patents

Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Info

Publication number
SE0303513D0
SE0303513D0 SE0303513A SE0303513A SE0303513D0 SE 0303513 D0 SE0303513 D0 SE 0303513D0 SE 0303513 A SE0303513 A SE 0303513A SE 0303513 A SE0303513 A SE 0303513A SE 0303513 D0 SE0303513 D0 SE 0303513D0
Authority
SE
Sweden
Prior art keywords
fatty acid
body weight
epa
acid composition
omega
Prior art date
Application number
SE0303513A
Other languages
English (en)
Swedish (sv)
Inventor
Morten Bryhn
Jan Kopecky
Original Assignee
Pronova Biocare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biocare As filed Critical Pronova Biocare As
Priority to SE0303513A priority Critical patent/SE0303513D0/xx
Publication of SE0303513D0 publication Critical patent/SE0303513D0/xx
Priority to ES04806374.7T priority patent/ES2451030T3/es
Priority to US10/582,978 priority patent/US9282760B2/en
Priority to CNA2004800402112A priority patent/CN1901897A/zh
Priority to EP04806374.7A priority patent/EP1699449B1/fr
Priority to PL04806374T priority patent/PL1699449T3/pl
Priority to PCT/IB2004/004178 priority patent/WO2005060954A1/fr
Priority to JP2006544592A priority patent/JP2007514733A/ja
Priority to CA2549103A priority patent/CA2549103C/fr
Priority to NZ547831A priority patent/NZ547831A/en
Priority to CN2012102238157A priority patent/CN102861004A/zh
Priority to EP10183626A priority patent/EP2301530A1/fr
Priority to AU2004305325A priority patent/AU2004305325B2/en
Priority to NO20063328A priority patent/NO336507B1/no
Priority to JP2012123615A priority patent/JP2012211147A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
SE0303513A 2003-12-19 2003-12-19 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof SE0303513D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE0303513A SE0303513D0 (sv) 2003-12-19 2003-12-19 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
AU2004305325A AU2004305325B2 (en) 2003-12-19 2004-12-17 Use of a fatty acid composition comprising at least one of EPA and DHA or any combinations thereof
PCT/IB2004/004178 WO2005060954A1 (fr) 2003-12-19 2004-12-17 Utilisation d'une composition d'acides gras comprenant au moins un epa et un dha ou des combinaisons de ceux-ci
CA2549103A CA2549103C (fr) 2003-12-19 2004-12-17 Utilisation d'une composition d'acides gras comprenant au moins un epa et un dha ou des combinaisons de ceux-ci
CNA2004800402112A CN1901897A (zh) 2003-12-19 2004-12-17 含有epa和dha中至少一种或者它们的任意组合的脂肪酸组合物的应用
EP04806374.7A EP1699449B1 (fr) 2003-12-19 2004-12-17 Utilisation d'une composition d'acides gras comprenant au moins un epa et un dha ou des combinaisons de ceux-ci
PL04806374T PL1699449T3 (pl) 2003-12-19 2004-12-17 Zastosowanie kompozycji kwasów tłuszczowych obejmującej co najmniej jeden z EPA i DHA lub jakąkolwiek ich kombinację
ES04806374.7T ES2451030T3 (es) 2003-12-19 2004-12-17 Uso de una composición de ácidos grasos que comprende al menos uno de EPA y DHA o cualesquiera combinaciones de los mismos
JP2006544592A JP2007514733A (ja) 2003-12-19 2004-12-17 Ｅｐａ及びｄｈａの少なくとも１つ又はこれらのいずれかの組み合わせを含む脂肪酸組成物の使用
US10/582,978 US9282760B2 (en) 2003-12-19 2004-12-17 Use of a fatty acid composition comprising at least one of EPA and DHA or any combinations thereof
NZ547831A NZ547831A (en) 2003-12-19 2004-12-17 Use of a fatty acid composition comprising at least one of EPA and DHA or any combinations thereof
CN2012102238157A CN102861004A (zh) 2003-12-19 2004-12-17 含有epa和dha中至少一种或者它们的任意组合的脂肪酸组合物的应用
EP10183626A EP2301530A1 (fr) 2003-12-19 2004-12-17 Utilisation d´une composition d´acides gras comprenant EPA et DHA pour la reduction de la masse corporelle
NO20063328A NO336507B1 (no) 2003-12-19 2006-07-18 Anvendelse av en fettsyresammensetning som innbefatter EPA og DHA
JP2012123615A JP2012211147A (ja) 2003-12-19 2012-05-30 Ｅｐａ及びｄｈａの少なくとも１つ又はこれらのいずれかの組み合わせを含む脂肪酸組成物の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303513A SE0303513D0 (sv) 2003-12-19 2003-12-19 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Publications (1)

Publication Number Publication Date
SE0303513D0 true SE0303513D0 (sv) 2003-12-19

Family

ID=30768831

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0303513A SE0303513D0 (sv) 2003-12-19 2003-12-19 Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Country Status (12)

Country Link
US (1) US9282760B2 (fr)
EP (2) EP1699449B1 (fr)
JP (2) JP2007514733A (fr)
CN (2) CN1901897A (fr)
AU (1) AU2004305325B2 (fr)
CA (1) CA2549103C (fr)
ES (1) ES2451030T3 (fr)
NO (1) NO336507B1 (fr)
NZ (1) NZ547831A (fr)
PL (1) PL1699449T3 (fr)
SE (1) SE0303513D0 (fr)
WO (1) WO2005060954A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017627A2 (fr) * 2004-08-06 2006-02-16 Barry Sears Compositions dietetiques et procedes d'utilisation dans le traitement de l'insulinoresistance
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
PL1800675T4 (pl) 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
CN101370490A (zh) * 2005-12-29 2009-02-18 希尔氏宠物营养品公司 用于预防或治疗炎症性肠病的组合物及其制备方法
BRPI0708378A2 (pt) * 2006-02-28 2011-06-07 Bristol Myers Squibb Co uso de dha e ara na preparação de uma composição para prevenção ou tratamento de obesidade
EP1886680A1 (fr) * 2006-05-23 2008-02-13 Nestec S.A. Supplément pour futures mamans
CA2660291C (fr) * 2006-08-09 2011-11-22 The Iams Company Procede permettant d'ameliorer la sante des os et la sante musculaire
RU2509071C2 (ru) 2006-11-01 2014-03-10 Пронова Биофарма Норге Ас Новые липидные соединения
KR101438177B1 (ko) 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
BRPI0717972A2 (pt) * 2006-11-01 2013-11-12 Pronova Biopharma Norge As Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar)
CN101646426A (zh) * 2006-11-03 2010-02-10 普罗诺瓦生物医药挪威公司 ω-3脂质化合物
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20090197955A1 (en) * 2008-01-31 2009-08-06 Monsanto Company Methods of improving dha deposition and related function and/or development
WO2009134147A1 (fr) * 2008-05-02 2009-11-05 Pronova Biopharma Norge As Compositions lipidiques renfermant des dérivés d’epa et de dha et leur utilisation
EP3578177A1 (fr) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Composition pharmaceutique contenant de l'acide eicosapentaénoïque et leurs procédés d'utilisation
AU2010222648B2 (en) * 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US8207363B2 (en) * 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
CA2765329C (fr) 2009-06-12 2018-01-02 Calanus As Composition d'huile de copepode, formulations comportant la composition d'huile, et leurs utilisations pour reduire l'accumulation de graisse viscerale, ameliorer la tolerance au glucose et empecher ou traiter des maladies et des troubles lies a l'obesite
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011048493A1 (fr) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Capsules ou comprimés enrobés d'un mélange oléagineux d'acides gras
CA2993690C (fr) 2010-01-19 2022-03-22 Dsm Ip Assets B.V. Micro-organismes produisant de l'acide eicosapentaenoique, compositions d'acides gras et leurs procedes de fabrication et d'utilisation
JP5576699B2 (ja) * 2010-04-15 2014-08-20 花王株式会社 Ｇｉｐ上昇抑制剤
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
JP2014502165A (ja) * 2010-12-20 2014-01-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 満腹応答を誘導するためのペットフード組成物
WO2013005834A1 (fr) * 2011-07-07 2013-01-10 持田製薬株式会社 Agent anti-obésité comprenant de l'epa de haute pureté
EA035287B1 (ru) 2011-07-21 2020-05-25 ДСМ АйПи АССЕТС Б.В. Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
JP2013063937A (ja) * 2011-09-20 2013-04-11 Kao Corp Ｇｉｐ上昇抑制剤
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (fr) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
SG11201403805WA (en) 2012-01-06 2014-08-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
AU2013240427B2 (en) 2012-03-30 2017-08-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
AR095182A1 (es) 2012-05-07 2015-09-30 Omthera Pharmaceuticals Inc Composiciones de estatinas y ácidos grasos omega-3
BR112014032905B1 (pt) 2012-06-29 2022-02-22 Amarin Pharmaceuticals Ireland Limited Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
PT3626806T (pt) 2013-12-20 2024-07-31 Mara Renewables Corp Métodos para recuperar óleo de microrganismos
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
CN107970232A (zh) * 2016-10-21 2018-05-01 玛鲁哈日鲁株式会社 含n-3系不饱和脂肪酸的组合物、及n-3系不饱和脂肪酸在该组合物的制造中的应用
WO2018116093A1 (fr) 2016-12-22 2018-06-28 MARA Renewables Corporation Procédés de production de biomasse riche en dha, acide palmitique et protéine à l'aide d'un micro-organisme eucaryote
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
WO2018213663A1 (fr) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite
EP3661600A4 (fr) 2017-10-23 2021-08-11 Epitracker, Inc. Analogues d'acides gras et leur utilisation dans le traitement des états liés au syndrome métabolique
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
CN108721269A (zh) * 2018-07-10 2018-11-02 广东海洋大学 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CN109463512A (zh) * 2018-12-10 2019-03-15 瞿瀚鹏 Dha油脂组合物在凝胶糖果中的应用以及凝胶糖果及其制备方法
CN109646430A (zh) * 2018-12-26 2019-04-19 江南大学 n-3多不饱和脂肪酸在制备预防沙门氏菌感染药物中的应用
EP3908374A4 (fr) 2019-01-09 2022-12-28 Epitracker, Inc. Compositions et méthodes pour le diagnostic et le traitement de maladies neurodégénératives
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
CN114980973A (zh) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
WO2021158842A1 (fr) * 2020-02-06 2021-08-12 Dsm Ip Assets B.V. Méthode pour augmenter le taux d'acide eicosapentaénoïque dans le plasma d'un animal
AU2021245403A1 (en) 2020-04-03 2022-11-24 MARA Renewables Corporation Microbial oils with high levels of omega-3 fatty acids
AU2021329343A1 (en) * 2020-08-20 2023-03-09 Epitracker, Inc. Compositions and methods for treatment of obesity
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2023080939A1 (fr) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadécanoylcarnitine pour le traitement d'affections liées à la qualité du vieillissement et à la longévité

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565667A (en) * 1896-08-11 Churn
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
JPH0394655A (ja) 1989-09-06 1991-04-19 Otsuka Pharmaceut Co Ltd 栄養補給用組成物
JPH0398560A (ja) 1989-09-09 1991-04-24 Toa Kogyo Kk 餃子と餃子製造機の成形用形枠
US5013569A (en) 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
JP3092180B2 (ja) 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
JP3098560B2 (ja) * 1991-03-28 2000-10-16 花王株式会社 体重増加抑制剤
JPH06116585A (ja) 1992-10-09 1994-04-26 Kanegafuchi Chem Ind Co Ltd 油脂の精製方法
TW360501B (en) * 1996-06-27 1999-06-11 Nestle Sa Dietetically balanced milk product
ATE497384T1 (de) 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
JP2872986B1 (ja) 1998-01-21 1999-03-24 池田食研株式会社 高純度高度不飽和脂肪酸の低級アルコールエステル精製方法
US6596302B2 (en) * 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
JP2002188096A (ja) * 2000-10-12 2002-07-05 Kanegafuchi Chem Ind Co Ltd 新規なグリセリドおよびその製造法並びにその用途
JP2002180082A (ja) 2000-12-11 2002-06-26 Maruha Corp 摂取物
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
JP4337273B2 (ja) 2001-04-20 2009-09-30 日本水産株式会社 基礎代謝増進剤
AU2002320407A1 (en) * 2001-07-10 2003-01-29 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
US20030203004A1 (en) * 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
TW200412942A (en) * 2002-08-06 2004-08-01 Abbott Lab Appetite control method
WO2004018598A1 (fr) 2002-08-07 2004-03-04 Kao Corporation Composition grasse

Also Published As

Publication number Publication date
NO336507B1 (no) 2015-09-14
JP2007514733A (ja) 2007-06-07
JP2012211147A (ja) 2012-11-01
AU2004305325B2 (en) 2008-02-07
EP1699449A1 (fr) 2006-09-13
NO20063328L (no) 2006-09-19
CN102861004A (zh) 2013-01-09
EP1699449B1 (fr) 2014-01-22
AU2004305325A1 (en) 2005-07-07
ES2451030T3 (es) 2014-03-26
WO2005060954A1 (fr) 2005-07-07
PL1699449T3 (pl) 2014-06-30
CN1901897A (zh) 2007-01-24
US9282760B2 (en) 2016-03-15
NZ547831A (en) 2009-11-27
CA2549103A1 (fr) 2005-07-07
EP2301530A1 (fr) 2011-03-30
US20070112071A1 (en) 2007-05-17
CA2549103C (fr) 2013-11-26

Similar Documents

Publication Publication Date Title
SE0303513D0 (sv) Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
TW429145B (en) Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
WO2006017627A3 (fr) Compositions dietetiques et procedes d'utilisation dans le traitement de l'insulinoresistance
CA2229624A1 (fr) Methode pour reduire le poids corporel et pour traiter l'obesite
KR940021057A (ko) 흡연의 악영향을 완화시키기 위한 조성물
FR2635263B1 (fr)
ID24710A (id) Komposisi nutrisi untuk perawatan luka karena tekanan
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
DE69935995D1 (de) Polyungesättigen fettsäuren nährungsergänzung
PT1216041E (pt) Dieta com elevado teor de lipidos
ATE291910T1 (de) Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
GB9217780D0 (en) Fatty acid treatment
WO2000040705A3 (fr) Gene desaturase humain et ses utilisations
KR940018091A (ko) 불포화 지방산을 포함하는 처방
JPS6422819A (en) Amnesia treating or preventing composition
PL368188A1 (en) Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level
DE59303744D1 (de) Mittel zur Behandlung des atopischen Ekzems und anderen entzündlichen Hautkrankheiten
DE60101859D1 (de) Pinolensäure gegen Diabetes
DE3750426D1 (de) Mittel zur Verbesserung spezifischer Eigenschaften des Blutes.
DE60329588D1 (de) Verwendung von epa and dha zur sekundären prevention von schlaganfällen
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
AU6669096A (en) Drugs for prevention and treatment of diseases caused by abnormalities in cartilage tissues